Related Experiment Video
Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Epigenetic changes in pediatric solid tumors: promising new targets
Elizabeth R Lawlor1, Carol J Thiele
1Department of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA. elawlor@umich.edu
Abstract:
Cancer is being reinterpreted in the light of recent discoveries related to the histone code and the dynamic nature of epigenetic regulation and control of gene programs during development, as well as insights gained from whole cancer genome sequencing. Somatic mutations in or deregulated expression of genes that encode chromatin-modifying enzymes are being identified with high frequency. Nowhere is this more relevant than in pediatric embryonal solid tumors. A picture is emerging that shows that classic genetic alterations associated with these tumors ultimately converge on the epigenome to dysregulate developmental programs. In this review, we relate how alterations in components of the transcriptional machinery and chromatin modifier genes contribute to the initiation and progression of pediatric solid tumors. We also discuss how dramatic progress in our understanding of the fundamental mechanisms that contribute to epigenetic deregulation in cancer is providing novel avenues for targeted cancer therapy.
Insights
Epigenetic deregulation, driven by histone code and chromatin modifier gene alterations, is key in pediatric solid tumors. Understanding these mechanisms offers new pathways for targeted cancer therapies.
Area of Science:
- Oncology
- Epigenetics
- Developmental Biology
Background:
- Cancer is increasingly understood through the lens of epigenetics, particularly the histone code and gene regulation during development.
- Whole cancer genome sequencing reveals frequent somatic mutations and deregulated expression of chromatin-modifying enzymes.
- Pediatric embryonal solid tumors are a critical area where these epigenetic insights are highly relevant.
Purpose of the Study:
- To review how alterations in transcriptional machinery and chromatin modifier genes initiate and progress pediatric solid tumors.
- To discuss the convergence of classic genetic alterations on the epigenome in these tumors.
- To highlight novel therapeutic avenues emerging from understanding epigenetic deregulation in cancer.
Main Methods:
- Review of current literature on cancer epigenetics, focusing on pediatric solid tumors.
- Analysis of findings from whole cancer genome sequencing studies.
- Integration of knowledge regarding the histone code and epigenetic regulation.
Main Results:
- Somatic mutations and altered expression of chromatin-modifying enzymes are frequently observed in pediatric solid tumors.
- Genetic alterations in these tumors converge on the epigenome, disrupting developmental gene programs.
- Epigenetic deregulation plays a crucial role in the initiation and progression of pediatric solid tumors.
Conclusions:
- Alterations in chromatin modifiers and transcriptional machinery are central to pediatric solid tumor development.
- A deeper understanding of epigenetic mechanisms provides a foundation for developing targeted cancer therapies.
- The epigenome is a critical target for future therapeutic strategies in pediatric oncology.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Epigenetic Regulation
X-chromosome...
Pharmacogenomics: Identification of New Drug Targets
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation
